Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma

Figure 5 Reduction in hepatocellular carcinoma tumor size with knockdown of polo-like kinase 1. A: Treatment of short-interfering RNA (siRNA) against polo-like kinase 1 (PLK1) (si-PLK1, n = 6) in nude mice impeded the tumor growth compared with short interfering non-targeting (si-NT) (n = 6) or the non-treatment group (n = 6). Huh-7 tumor-bearing nude mice were treated with 1 nmol/L si-PLK1 intratumoral injections every alternate day for 27 d. Data are shown as mean ± SE, using the Student t-test (^aP < 0.05); B: Images of nude mice with their tumors at day 27. The left panel shows a reduction in tumor size of subcutaneous tumors in nude mice treated with si-PLK1, while the right panel shows similar mice treated with si-NT.